Updates are available Correction dated 2020-11-13
Click to view Correction: https://doi.org/10.1007/s00125-020-05311-4
-
Authors
,
Koivula, Robert W. http://orcid.org/0000-0002-1646-4163
Atabaki-Pasdar, Naeimeh
Giordano, Giuseppe N.
White, Tom
Adamski, Jerzy
Bell, Jimmy D.
Beulens, Joline
Brage, Søren
Brunak, Søren
De Masi, Federico
Dermitzakis, Emmanouil T.
Forgie, Ian M.
Frost, Gary
Hansen, Torben
Hansen, Tue H.
Hattersley, Andrew
Kokkola, Tarja
Kurbasic, Azra
Laakso, Markku
Mari, Andrea
McDonald, Timothy J.
Pedersen, Oluf
Rutters, Femke
Schwenk, Jochen M.
Teare, Harriet J. A.
Thomas, E. Louise
Vinuela, Ana
Mahajan, Anubha
McCarthy, Mark I.
Ruetten, Hartmut
Walker, Mark
Pearson, Ewan
Pavo, Imre
Franks, Paul W.
-
Funding
Funding for this research was provided by:
European Commission (CoG-2015_681742_NASCENT [P.W.F.])
Novo Nordisk (STAR Novo Nordisk co-financed PhD fellowship [R.W.)
Innovative Medicines Initiative (115317 (DIRECT))
Medical Research Council (MC_UU_12015/3 [S.Bra.])
MedImmune (PhD Fellowship [T.W.])
Novo Nordisk Fonden (NNF18OC0031650 (Postdoctoral Fellowship)[R.W.K.])
- License Information
-
More Information
Article History
Received: 29 August 2019
Accepted: 29 November 2019
First Online: 30 January 2020
Change Date: 13 November 2020
Change Type: Correction
Change Details: Unfortunately, ���Present address��� was omitted from one of the addresses provided for Mark I. McCarthy (#26).
Duality of interest
: IP is an employee of Eli Lilly GmbH, Vienna, Austria. HR is an employee of Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany. This does not alter our adherence to Diabetologia’s policies on sharing data and materials. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. MIMcC has served on advisory panels for Pfizer, Novo Nordisk and Zoe Global, received honoraria from Merck, Pfizer, Novo Nordisk and Eli Lilly and research funding from AbbVie, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Pfizer, Roche, Sanofi-Aventis, Servier and Takeda. As of June 2019, MIMcC is an employee of Genentech, and a holder of Roche stock. All other authors declare that there is no duality of interest associated with their contribution to this manuscript.
